GLP-1s, SGLT2s, and Oral Hypoglycemic Agents: Diabetes Treatment Options

Glucagon-like peptide-1 receptor agonists are all the rage in the diabetes space, but other medications, including sodium-glucose cotransporter 2 inhibitors and oral hypoglycemic agents, still have a place in diabetes management. Learn more about these medications with a selection of abstracts presented at the American Diabetes Association 84th Scientific Sessions, held June 21 to 24, 2024, in Orlando, Florida.

READ MORE: Diabetes Resource Center

References

1. Amamoo J, Doshi RP, Noone J, et al. Real-world impact of once-weekly injectable semaglutide (sema OW) vs. sodium–glucose cotransporter 2 inhibitors (SGLT2i) on HbA1c, weight, and health care resource utilization (HCRU) outcomes in type 2 diabetes (T2D)—an observational study (PAUSE). Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 1884-LB.

2. Ortiz RV, Ordoñez NF, Gallifa EN, et al. Glycemic control in patients with type 2 diabetes mellitus with A1C ≥9.0% with oral hypoglycemic agents vs. insulin plus oral agents. Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 1891-LB.

3. Paik JM, Tesfaye H, Cromer SJ, et al. Safety of newer glucose medications in adults with type 2 diabetes and low to moderate CV risk. Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 939-P.

4. Ueberall MA, Quandel T, Engelen S, et al. Impact of ongoing treatment with high concentration capsaicin topical system on affective distress and quality of life in patients with painful diabetic neuropathy—a retrospective cohort study. Presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, FL. Abstract 1892-LB.